Theradiag SA
PAR:ALTER

Watchlist Manager
Theradiag SA Logo
Theradiag SA
PAR:ALTER
Watchlist
Price: 1.26 EUR Market Closed
Market Cap: 16.4m EUR
Have any thoughts about
Theradiag SA?
Write Note

Theradiag SA
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Theradiag SA
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Theradiag SA
PAR:ALTER
Cash from Operating Activities
-€1.2m
CAGR 3-Years
0%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Edap Tms SA
NASDAQ:EDAP
Cash from Operating Activities
€4.5m
CAGR 3-Years
31%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biomerieux SA
PAR:BIM
Cash from Operating Activities
€494.6m
CAGR 3-Years
-7%
CAGR 5-Years
3%
CAGR 10-Years
7%
Carmat SA
PAR:ALCAR
Cash from Operating Activities
-€48.6m
CAGR 3-Years
3%
CAGR 5-Years
-3%
CAGR 10-Years
-12%
Visiomed Group SA
PAR:ALVMG
Cash from Operating Activities
€1.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amplitude Surgical SA
PAR:AMPLI
Cash from Operating Activities
€4m
CAGR 3-Years
20%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
No Stocks Found

Theradiag SA
Glance View

Market Cap
16.4m EUR
Industry
Health Care

Theradiag SA engages in the distribution, development and manufacturing of in vitro diagnostic and theranostics tests. The company is headquartered in Croissy-Beaubourg, Ile-De-France. The company went IPO on 2012-12-11. The firm develops and offers product panels for diagnosing autoimmune diseases, allergies, and infectious diseases. TheraDiags product offering consists of tests using a range of techniques (Elisa, rapid tests, immunofluorescence, Dot, immunochemical tests, molecular biology, etc.) as well as a range of automatic devices and solutions for high-speed diagnostics based on Luminexs Multiplex technology. The company has also developed a range of theranostic diagnostics commercialized under the Lisa-Tracker brand which provide monitoring of patients treated by anti-TNF monoclonal antibodies. TheraDiag is active in more than 30 countries, as an independent distributor.

ALTER Intrinsic Value
1.36 EUR
Undervaluation 7%
Intrinsic Value
Price

See Also

What is Theradiag SA's Cash from Operating Activities?
Cash from Operating Activities
-1.2m EUR

Based on the financial report for Jun 30, 2023, Theradiag SA's Cash from Operating Activities amounts to -1.2m EUR.

What is Theradiag SA's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
6%

Over the last year, the Cash from Operating Activities growth was 0%.

Back to Top